Navigation Links
Signal may send cancer's cellular factories into overdrive
Date:7/9/2014

A network of signals active in almost all types of cancer sends the protein factories in our cells into overdrive, and may help fuel a tumour's uncontrolled growth, new research suggests.

Scientists at The Institute of Cancer Research, London, identified a molecular trigger responsible for ratcheting up activity of the endoplasmic reticulum (ER) the cellular factory that makes the building blocks cancer cells need to keep growing.

A protein in the TOR signalling pathway, called SREBP, controls the flow of messages to the endoplasmic reticulum telling it to expand and could allow cancer cells to produce enough proteins and lipids to fuel their non-stop growth.

The findings may help to explain how cancer cells maintain their high levels of metabolism and could uncover future targets for cancer treatment.

The study was published in the journal PLOS ONE, and funded by the Biotechnology and Biological Sciences Research Council (BBSRC), with additional support from the Wellcome Trust.

Unlike healthy cells, cancer cells are constantly growing, and so need to keep making proteins and lipids - the building blocks of all cells.

In healthy cells constant growth can overwhelm cellular factories like the ER, leading to cell stress and death, but cancer cells manage to keep their factories running at high capacity to fuel non-stop growth.

Scientists at The Institute of Cancer Research (ICR) used the cells of fruit flies, modified with a fluorescent marker that is activated when the cells are put under stress, to identify the signals responsible for driving up activity of the ER.

They systematically silenced genes thought to be important to the smooth working of the ER and measured the stress signals produced in response.

They found that silencing the TOR signalling pathway - activated in many different types of cancer - increased ER stress in the cells. When they blocked TOR signals, cells took longer to recover from ER stress and the ER factory shrank.

Their findings suggest the TOR signalling pathway promotes cell growth while simultaneously ensuring productivity of the ER matches this growth. And the protein SREBP, which is part of the TOR signalling pathway, appeared to be essential for promoting expansion of the ER, and ensuring it carried out its factory activities effectively.

Lead author Dr Chris Bakal, leader of the Dynamical Cell Systems Team at The Institute of Cancer Research, London, said: "The endoplasmic reticulum is the factory of our cells, creating the proteins and lipids needed for our cells to grow and proliferate. In cancer cells, this factory is active all the time, churning out the building blocks that cancer cells need for their rapid growth.

"We have discovered the key role played by the TOR signalling pathway in driving the expansion of the endoplasmic reticulum, and sending a cell's factories into overdrive. The TOR pathway is active in many types of cancer, and our study provides new insights into how cancer metabolism works, and suggests that these metabolic signals could be excellent targets for future treatments."


'/>"/>
Contact: Graham Shaw
graham.shaw@icr.ac.uk
020-715-35380
Biotechnology and Biological Sciences Research Council
Source:Eurekalert

Related medicine news :

1. Signaling pathway may explain the body clocks link to mental illness
2. MAD: Scientists shed light on braking mechanisms in cellular signaling
3. Brain signals link physical fitness to better language skills in kids
4. Signals found that recruit host animals cells, enabling breast cancer metastasis
5. Nightmares may signal a child is being bullied
6. DNA modifications measured in blood signal related changes in the brain
7. Molecular aberration signals cancer
8. Tinnitus study signals advance in understanding link between loud sounds exposure and hearing loss
9. Long distance signals protect brain from viral infections
10. Prostate cancer signal reawakens sleeper agent cells in bones
11. App may signal cellphone dependency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Farmville, NC (PRWEB) , ... January 20, 2017 ... ... the vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in ... article by Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Land of More and ... the issue of world hunger, and shares the simple and achievable answer. “The Land ... and member of the Fairview Missionary Church in Angola, Indiana where he works with ...
(Date:1/19/2017)... ... January 19, 2017 , ... Next week after January 20th, the ... Congressional political games that circumvent health needs of over 30 million. Many interviews with ... anxieties and needs government public servants were suppose to prioritize. Interviews provided below. ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... innovators, engineers, and scientists from around the world, announces the launch of its ... quick and easy portal to research breakthroughs and trending news, vital information on ...
(Date:1/19/2017)... Park City, Utah (PRWEB) , ... January 19, ... ... Sundance Film Festival in a medical capacity this year. Drs. Alexander Paziotopoulos, Andrew ... Lounge to provide a condensed version of the clinic’s leading recovery program. ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 19, 2017  Sensus Healthcare, Inc. (NASDAQ: ... in the treatment of non-melanoma skin cancers and ... radiation therapy, today announced that it will report ... results on Thursday, February 2, 2017 after the market ... conference call with the investment community on Thursday, February ...
(Date:1/19/2017)... , January 19, 2017 Shire ... that the U.S. Food and Drug Administration (FDA) has ... New Drug Application (NDA) for SHP465, a long-acting, triple-bead, ... a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The ... around June 20, 2017, the designated Prescription Drug User ...
(Date:1/19/2017)... January 19, 2017 Pfizer ... the Milner Therapeutics Consortium   Major ... Cambridge   The Milner ... PFE ) as a partner to the Milner Therapeutics ... enables the efficient transfer of materials between industry and ...
Breaking Medicine Technology: